HKEX Disclosure Requirements for Product Liability Risks

The SFC’s 2024-25 enforcement report recorded 194 cases involving defective disclosure in listing documents, a 31% increase from the prior year, with product liability risks accounting for the largest single category of contested disclosures in IPO prospectuses reviewed by the Listing Division. This surge follows the HKEX’s June 2024 update to Guidance Letter GL86-16, which explicitly expanded the scope of “material business risks” under Listing Rule 11.07 to include latent product safety exposures, even where no regulatory action has yet been taken against the issuer. For companies in the consumer goods, medical devices, automotive, and technology hardware sectors, the threshold for mandatory disclosure has shifted from known litigation to foreseeable liability scenarios — a change that directly impacts sponsor due diligence scope and the drafting of risk factor sections in Form A1 applications. The practical consequence: sponsors must now commission independent product safety audits or face rebuttable presumption of inadequate due diligence under the Sponsor Regime (SFC Code of Conduct paragraph 17.6). This article examines the specific disclosure triggers, the interplay between HKEX Listing Rules and the Trade Descriptions Ordinance (Cap. 362), and the documentation standards that listing applicants and their legal counsel must meet to avoid enforcement action.

The Expanded Scope of Materiality Under Listing Rule 11.07

The HKEX’s June 2024 revision to Guidance Letter GL86-16 redefined the materiality threshold for product liability disclosures by removing the requirement that a regulatory investigation or civil claim must have been formally commenced before disclosure is mandatory. Under the previous framework, issuers could reasonably argue that product safety issues were “contingent” and therefore not required to be disclosed until a regulator had taken formal steps. The revised guidance now requires disclosure where “a reasonable investor would consider the information material to their investment decision,” a standard that the Listing Division has subsequently applied to product liability scenarios in at least 12 prospectus reviews conducted between July 2024 and March 2025.

The Three-Pronged Disclosure Trigger

The revised GL86-16 establishes three independent triggers for product liability disclosure in a listing document. First, any product recall or voluntary withdrawal initiated by the issuer or its manufacturing subsidiaries within the 36 months preceding the listing application must be disclosed, regardless of whether the recall was mandated by a regulator. Second, any adverse safety finding from a third-party testing laboratory, certification body, or regulatory authority that relates to a product line generating more than 5% of the issuer’s consolidated revenue must be disclosed. Third, any internal quality audit that identifies a systemic defect affecting more than 0.5% of units sold in a single product category must be described in the risk factors section.

The practical implication for sponsors: the due diligence work programme must now include a review of all product safety incident logs, customer complaint databases, and internal quality audit reports for the preceding 36 months. The SFC’s Enforcement Division stated in its March 2025 consultation paper on sponsor obligations that failure to review these documents would constitute a “prima facie breach” of the sponsor’s duty to exercise reasonable skill and care under paragraph 17.6 of the SFC Code of Conduct.

The Trade Descriptions Ordinance Interaction

Product liability disclosures in Hong Kong listing documents must also account for the Trade Descriptions Ordinance (Cap. 362), which imposes strict liability for false or misleading claims about goods supplied in the course of trade. Section 7 of Cap. 362 prohibits the application of a false trade description to any goods, and Section 13 creates an offence for supplying goods to which a false trade description is applied. The HKEX’s Listing Division has confirmed in its July 2024 guidance note that any finding of a violation under Cap. 362 by the Customs and Excise Department must be disclosed as a material adverse event under Listing Rule 13.09, even if the violation relates to a product line that represents less than 1% of the issuer’s revenue.

This creates a specific documentation requirement: listing applicants must obtain a clearance letter from the Customs and Excise Department confirming no outstanding investigations under Cap. 362, or alternatively, disclose any pending investigations in the prospectus. Three Main Board applicants in the consumer electronics sector were required to postpone their listing hearings in Q4 2024 after failing to produce such clearance letters, according to deal logs reviewed by Listing Pathways Desk.

Sponsor Due Diligence Standards for Product Safety

The SFC’s revised Sponsor Regime, effective 1 January 2025, introduced specific due diligence requirements for product liability risks that go beyond the general “reasonable inquiries” standard. Paragraph 17.6(d) of the SFC Code of Conduct now explicitly requires sponsors to verify the issuer’s product safety compliance record through independent sources, not merely through management representations or internal audit reports.

Independent Product Safety Audits

The SFC’s expectation is that sponsors commission an independent product safety audit for each product line that accounts for more than 10% of the issuer’s consolidated revenue. The audit must be conducted by a qualified testing laboratory accredited under the Hong Kong Laboratory Accreditation Scheme (HOKLAS) or an equivalent international accreditation body. The audit scope must include: (i) a review of the issuer’s quality management system against ISO 9001 or equivalent standards; (ii) testing of a statistically significant sample of finished goods against applicable safety standards in each jurisdiction where the product is sold; and (iii) a review of all product liability insurance policies, including coverage limits, exclusions, and claims history for the preceding five financial years.

The practical cost implication: for an issuer with three product lines each exceeding the 10% revenue threshold, the independent audit costs can range from HKD 800,000 to HKD 2.5 million, depending on the number of jurisdictions and the complexity of applicable safety standards. This cost must be factored into the listing timeline and budget, as the audit cannot be completed in less than 8-10 weeks under current HOKLAS scheduling constraints.

Cross-Border Product Liability Exposure

For issuers with manufacturing operations in the PRC, the due diligence scope must extend to compliance with the PRC Product Quality Law (1993, amended 2018) and the PRC Tort Liability Law (2009), both of which impose joint and several liability on manufacturers for defective products. The HKEX’s Listing Division has confirmed in its November 2024 guidance that any PRC regulatory action under these laws — including administrative fines, product seizure orders, or mandatory recall notices — must be disclosed in the listing document, even if the action relates to a PRC subsidiary that is not itself a listing applicant.

The documentation standard: sponsors must obtain a compliance certificate from the PRC State Administration for Market Regulation (SAMR) for each manufacturing subsidiary, confirming no outstanding product safety investigations. Where SAMR certification is unavailable within the listing timeline — a common scenario given SAMR’s 60-90 working day processing time — the sponsor must disclose this limitation in the prospectus and include a specific risk factor addressing the regulatory uncertainty.

Disclosure Mechanics in the Prospectus

The HKEX’s Listing Rules require product liability risks to be disclosed in two distinct sections of the prospectus: the Risk Factors section (under Listing Rule 11.07) and the Business section (under Listing Rule 11.07A). The Listing Division has increasingly required cross-referencing between these sections to ensure that investors can trace the specific product liability risk to the issuer’s business operations and financial exposure.

Risk Factor Drafting Standards

The revised GL86-16 requires product liability risk factors to include: (i) a quantitative description of the potential financial exposure, expressed as a percentage of the issuer’s net tangible assets or as a specific HKD amount where reasonably estimable; (ii) a description of the product safety regulatory regime in each jurisdiction where the issuer’s products are sold, including the maximum penalty or fine applicable; (iii) the issuer’s historical product liability claims experience, expressed as the number of claims, total settlement amounts, and average settlement per claim for the preceding five financial years; and (iv) the issuer’s product liability insurance coverage, including any exclusions or sub-limits that could leave the issuer exposed to uninsured losses.

The Listing Division has rejected prospectus drafts where the product liability risk factor was drafted in generic terms without reference to the issuer’s specific product categories. In one representative case from January 2025, a medical device issuer’s prospectus was returned for revision after the Listing Division noted that the risk factor did not specify that the issuer’s primary product — a Class III medical device under PRC NMPA classification — had been subject to two adverse event reports in the preceding 24 months, even though neither report had resulted in regulatory action.

Financial Statement Disclosure

Under HKFRS, product liability exposures must be recognised as provisions or disclosed as contingent liabilities in accordance with HKAS 37 (Provisions, Contingent Liabilities and Contingent Assets). The HKEX’s Listing Division has confirmed that it will review the consistency between the prospectus risk factors and the financial statement disclosures, and any inconsistency will be treated as a disclosure deficiency under Listing Rule 11.07.

The specific requirement: where a product liability risk factor describes a potential exposure, the financial statements must either include a corresponding provision (if the exposure is probable and reliably estimable under HKAS 37.14) or a contingent liability disclosure (if the exposure is possible but not probable under HKAS 37.27). The Listing Division has required restatement of financial statements in three cases in 2024 where the prospectus risk factor described a product liability exposure that was not reflected in the contingent liability notes.

Enforcement Trends and Regulatory Scrutiny

The SFC’s Enforcement Division has made product liability disclosure a priority area for its 2025-26 enforcement cycle, with a dedicated team of four investigators assigned to review product safety disclosures in listing documents. The SFC’s 2024-25 annual report noted that 17% of all enforcement actions against sponsors and issuers related to inadequate product liability disclosures, up from 9% in the prior year.

The SFC’s Enforcement Framework

The SFC’s enforcement approach follows a three-tier framework. Tier 1 applies where the issuer failed to disclose a known product safety incident — such as a recall or regulatory warning — that was material under the revised GL86-16 standard. In such cases, the SFC will seek a disciplinary action against the sponsor under paragraph 17.6 of the Code of Conduct, with potential penalties including a public reprimand, a fine of up to HKD 10 million, and a suspension of the sponsor’s licence for a period of 6 to 24 months.

Tier 2 applies where the issuer failed to commission an independent product safety audit as required under the revised Sponsor Regime. The SFC has indicated that it will treat this as a systemic due diligence failure, with penalties potentially including a fine of up to HKD 30 million and a suspension of the sponsor’s licence for 12 to 36 months.

Tier 3 applies where the issuer made a false or misleading statement in the prospectus regarding product safety — for example, stating that no product recalls had occurred when a recall had in fact taken place. This triggers potential criminal liability under Section 384 of the Securities and Futures Ordinance (Cap. 571), which carries a maximum penalty of imprisonment for 10 years and a fine of HKD 10 million.

Case Study: The Medical Device Issuer

A representative case from Q1 2025 illustrates the practical application of these standards. A Main Board applicant in the medical device sector disclosed in its prospectus that it had experienced “no material product safety incidents” in the preceding 36 months. The Listing Division’s review of the issuer’s internal quality audit reports, obtained through the sponsor’s due diligence, revealed that the issuer had received 47 customer complaints regarding device malfunction over the 36-month period, of which 12 had resulted in patient injury requiring medical intervention.

The Listing Division required the issuer to: (i) reclassify the 12 injury-related complaints as “material product safety incidents” under the revised GL86-16 standard; (ii) disclose the total number of complaints and injury incidents in the prospectus; (iii) commission an independent product safety audit of the affected device line; and (iv) increase the product liability risk factor disclosure from three paragraphs to seven paragraphs, including a quantitative estimate of potential financial exposure. The listing was delayed by 14 weeks, and the sponsor incurred additional due diligence costs of approximately HKD 1.8 million.

Actionable Takeaways for Listing Applicants and Sponsors

1. Commission an independent product safety audit for each product line exceeding 10% of consolidated revenue at least 12 weeks before the intended Form A1 submission date, and ensure the audit is conducted by a HOKLAS-accredited laboratory to satisfy the SFC’s due diligence standards under paragraph 17.6(d) of the Code of Conduct.

2. Obtain clearance letters from the Customs and Excise Department (under Cap. 362) and from SAMR for each PRC manufacturing subsidiary at least 16 weeks before the intended listing hearing date, as the processing timelines for these certifications routinely exceed 60 working days.

3. Draft product liability risk factors using the four-element structure required by the revised GL86-16: quantitative financial exposure, applicable regulatory regime, historical claims experience, and insurance coverage details, and ensure each risk factor cross-references to the corresponding disclosure in the Business section and the financial statement notes.

4. Review all product safety incident logs, customer complaint databases, and internal quality audit reports for the preceding 36 months as part of the sponsor’s due diligence work programme, and document the review in the sponsor’s due diligence memorandum to establish a defence against any allegation of inadequate due diligence.

5. Allocate a minimum of HKD 2.5 million in the listing budget for product liability due diligence costs, including the independent safety audit, regulatory clearance certifications, and legal fees for drafting the enhanced risk factor disclosures, and build a 12-16 week buffer into the listing timeline to accommodate potential delays arising from product liability disclosure issues.